Long-term use of corticosteroids is associated with numerous adverse effects, particularly in children, but guidance is lacking on how to manage low-dose prednisone in clinically quiescent disease. In The Great Debate at ACR Convergence 2025—Corticosteroids in Pediatric SLE: Slay or Stay, two pediatric lupus experts took to the stage to explore this important topic.
Review 28 recommendations covering proteinuria screening, biopsy indications & triple therapy regimens for lupus nephritis.
Dr. Philip Seo highlights the latest research into the assessment and treatment of giant cell arteritis presented during ACR Convergence 2025.
Long-term remission & control of CVD risk factors can reduce the risk of atherosclerosis in lupus; triple APL positivity raises the risk of CVD, study finds.
SLE treatment is rapidly evolving as new therapies are developed & approved. Here are 10 key insights for clinicians.
Summaries of selected research abstracts on the assessment & management of systemic vasculitis from ACR Convergence 2024.
A phase 2 study from Spiera et al. found that patients with glucocorticoid-dependent PMR taking the antibody-drug conjugate ABBV-154 had a longer time to flare compared with those taking placebo, supporting further investigation.
An overview of highlights from the 2025 ECIM meeting, including research on treatment options for systemic sclerosis, the management of PMR & autoimmune testing.
Results of the international SELECT-GCA study suggest that upadacitinib may be an effective new oral treatment for giant cell arteritis.
Reactive arthritis has proved to be a diagnostic & therapeutic challenge due to its diverse presentations.